Form D · Biotechnology
Kernal Biologics, Inc.
Cambridge, MA · CIK 0001684728
Offering snapshot reported Feb 25, 2022 · SEC filing
- Reported sold
- $20.1M Offering amount: $25.5M
- Investors reported
- 53 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2022 | Initial | $20,081,970 | No comparison | 53 | SEC filing |
| Aug 15, 2018 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Sep 15, 2016 | Initial | $350,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-435030
$10,471,689.25 of the offering was issued upon note conversions and conversions of SAFEs.
Source: Form D, filed Feb 25, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yusuf Erkul | Director, Executive |
| Catherine Moroski | Director, Executive |
| Oguzhan Yilmas | Director |
| Oguzhan Yilmaz | Director |
| Burak Yilmaz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
700 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139